[PCSK9 inhibitors: For which patients? For which indication? What to consider?]

MMW Fortschr Med. 2018 Jan;160(1):43-46. doi: 10.1007/s15006-018-0091-2.
[Article in German]
No abstract available

Keywords: PCSK9 antibodies; PCSK9 inhibitors; alirocumab; evolocumab.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / prevention & control
  • Cholesterol, LDL / blood
  • Humans
  • Hypolipidemic Agents* / administration & dosage
  • Hypolipidemic Agents* / pharmacology
  • Hypolipidemic Agents* / therapeutic use
  • PCSK9 Inhibitors*
  • Receptors, LDL
  • Serine Proteinase Inhibitors* / administration & dosage
  • Serine Proteinase Inhibitors* / pharmacology
  • Serine Proteinase Inhibitors* / therapeutic use

Substances

  • Cholesterol, LDL
  • Hypolipidemic Agents
  • PCSK9 Inhibitors
  • Receptors, LDL
  • Serine Proteinase Inhibitors
  • PCSK9 protein, human